2019
CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation
Esteghamat F, Broughton JS, Smith E, Cardone R, Tyagi T, Guerra M, Szabó A, Ugwu N, Mani MV, Azari B, Kayingo G, Chung S, Fathzadeh M, Weiss E, Bender J, Mane S, Lifton RP, Adeniran A, Nathanson MH, Gorelick FS, Hwa J, Sahin-Tóth M, Belfort-DeAguiar R, Kibbey RG, Mani A. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nature Genetics 2019, 51: 1233-1243. PMID: 31358993, PMCID: PMC6675645, DOI: 10.1038/s41588-019-0470-3.Peer-Reviewed Original ResearchConceptsEarly-onset atherosclerosisMetabolic syndromeMetabolic syndrome traitsWhole-exome sequence analysisAttractive therapeutic targetPlatelet hyperactivationInsulin levelsPlasma insulinPlasma levelsInsulin sensitivityInsulin secretionTherapeutic targetPlatelet activationDisease mechanismsSyndrome traitsAtherosclerosisFunction mutationsSyndromeNovel lossInsulinMutationsSecretion
2005
Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus
Wilson P, D’Agostino R, Parise H, Sullivan L, Meigs J. Metabolic Syndrome as a Precursor of Cardiovascular Disease and Type 2 Diabetes Mellitus. Circulation 2005, 112: 3066-3072. PMID: 16275870, DOI: 10.1161/circulationaha.105.539528.Peer-Reviewed Original ResearchConceptsCoronary heart diseaseMetabolic syndromeCardiovascular diseaseRelative riskAge-adjusted relative riskType 2 diabetes mellitusPopulation attributable risk estimatesNew cardiovascular diseaseMetabolic syndrome traitsMiddle-aged adultsDiabetes mellitusIncident casesHeart diseaseNew T2DMT2DMType 2SyndromeEvent ratesRisk estimatesDiseaseSyndrome traitsMellitusWomenMenRisk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply